1469 related articles for article (PubMed ID: 22397654)
1. Immunologic correlates of the abscopal effect in a patient with melanoma.
Postow MA; Callahan MK; Barker CA; Yamada Y; Yuan J; Kitano S; Mu Z; Rasalan T; Adamow M; Ritter E; Sedrak C; Jungbluth AA; Chua R; Yang AS; Roman RA; Rosner S; Benson B; Allison JP; Lesokhin AM; Gnjatic S; Wolchok JD
N Engl J Med; 2012 Mar; 366(10):925-31. PubMed ID: 22397654
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
4. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
5. The abscopal effect associated with a systemic anti-melanoma immune response.
Stamell EF; Wolchok JD; Gnjatic S; Lee NY; Brownell I
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):293-5. PubMed ID: 22560555
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
Libon F; Arrese JE; Rorive A; Nikkels AF
Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
[TBL] [Abstract][Full Text] [Related]
7. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
10. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
11. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
Golden EB; Demaria S; Schiff PB; Chachoua A; Formenti SC
Cancer Immunol Res; 2013 Dec; 1(6):365-72. PubMed ID: 24563870
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
Peggs KS; Quezada SA
Expert Rev Anticancer Ther; 2010 Nov; 10(11):1697-701. PubMed ID: 21080797
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Formenti SC; Rudqvist NP; Golden E; Cooper B; Wennerberg E; Lhuillier C; Vanpouille-Box C; Friedman K; Ferrari de Andrade L; Wucherpfennig KW; Heguy A; Imai N; Gnjatic S; Emerson RO; Zhou XK; Zhang T; Chachoua A; Demaria S
Nat Med; 2018 Dec; 24(12):1845-1851. PubMed ID: 30397353
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
15. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
18. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
Thaipisuttikul I; Chapman P; Avila EK
J Immunother; 2015; 38(2):77-9. PubMed ID: 25658617
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
Yuan J; Page DB; Ku GY; Li Y; Mu Z; Ariyan C; Gallardo HF; Roman RA; Heine AI; Terzulli SL; Ritter E; Gnjatic S; Ritter G; Jungbluth AA; Allison JP; Old LJ; Wolchok JD
Cancer Immun; 2010 Jan; 10():1. PubMed ID: 20052966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
